Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

ting stent with clinically important benefits for patients," said Gregg W. Stone, M.D., Columbia University Medical Center; chairman, Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III U.S. pivotal clinical trial for XIENCE V.

Clinical Data Supporting XIENCE V

The robust clinical program for XIENCE V includes long-term data from a total of 1,362 patients enrolled in the SPIRIT FIRST, SPIRIT II and SPIRIT III trials, as well as continued access and post-approval programs that will enroll more than 14,000 XIENCE V patients.

The FDA approved XIENCE V based, in large part, on superior results from the 1,002 patient SPIRIT III U.S. pivotal clinical trial, in which XIENCE V demonstrated statistical superiority to TAXUS on the study's primary endpoint of in-segment late loss (vessel renarrowing) at eight months, with a statistically significant 50 percent reduction (mean, 0.14 mm for XIENCE V vs. 0.28 mm for TAXUS). XIENCE V also demonstrated statistical non-inferiority to TAXUS in the co-primary endpoint of target vessel failure (TVF, cardiac events related to the stented vessel) at nine months, with an observed 20 percent reduction (7.2 percent for XIENCE V vs. 9.0 percent for TAXUS). TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

In May 2008, Abbott presented two-year data from the SPIRIT III trial demonstrating that XIENCE V continues to deliver positive clinical benefits for patients. At two years, the XIENCE V demonstrated the following key results:

-- A 45 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for TAXUS, p-value=0.004)*. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (MI) or ischemia-driv
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Boston, MA (PRWEB) July 29, 2014 ... the Library of Congress was recently awarded to Juliana ... in Stoneham, MA, for their project, “From an Egg, ... from among 3,000 final entries for the National History ... more than 300 historians and educators in Washington, D.C. ...
(Date:7/28/2014)... building materials using light, developed by researchers at the ... are often considered the realm of science fiction, such ... cloaked starships won,t be a reality for quite some ... materials with building blocks a few billionths of a ... that light flies through them, and works on large ...
(Date:7/28/2014)... 28, 2014 Proove Biosciences , ... be exhibiting data and research conducted through their latest ... Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The ... Hyatt Regency, in Orlando, Florida. , The ... competence of physicians who care for patients suffering specificity ...
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
Breaking Biology Technology:In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Building 'invisible' materials with light 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4
... introduces a,new accessory, MPX(TM) (Multiplex) Blotting System, for ... can be incorporated into a,variety of assays including ... transduction pathway analysis, or any,other common Western blotting ... 7 x 8.5 cm., Processing is as ...
... Cardium Therapeutics,(Amex: CXM ) and ... that,InnerCool has entered into a exclusive commercialization ... distributor of medical products.,N.G.C. Medical primarily sells ... interventional cardiology markets. They also provide,in-service management ...
... REDWOOD CITY, Calif., June 19 Cardica, Inc.,(Nasdaq: ... Ph.D., the,company,s president and chief executive officer, is scheduled ... Thursday, June 26, 2008,at 12:30 p.m. Eastern Time. The ... To access the live and subsequently archived webcast ...
Cached Biology Technology:LI-COR(R) Biosciences Introduces New Tools for High Throughput Western Blotting 2Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 6
(Date:7/28/2014)... He calls himself the bug hunter, but the target ... be found and identified with special methods and instruments. ... State Veterinary Diagnostic Laboratory at Kansas State University, recently ... enterovirus G, which is an important find in the ... cells, but didn,t know what it was," Hause said. ...
(Date:7/28/2014)... (July 28, 2014)The Brain & Behavior Research Foundation ... and Freedman Prizes, recognizing exceptional clinical and basic ... by NARSAD Young Investigator Grants. The grants enable ... neurobiological and psychosocial research for the prevention, early ... affect one in four people. , Six young ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Interfering with interferon 2
... common type of lung cancer are notoriously insensitive to ... cellular pathways that regulate responses to cisplatin have now ... the journal Cell Reports . The findings reveal ... how these patients will respond to chemotherapy, as well ...
... July 26, 2012 Administering high-doses of interleukin-2 (IL-2) has ... metastatic melanoma. An article published in the current ... peer-reviewed journal from Mary Ann Liebert, Inc. ( http://www.liebertpub.com ... the most effective. The article is available free ...
... July 26, 2012 Congenital hypothyroidism is thyroid hormone ... to neurocognitive impairments in infants and children. Although ... daily during pregnancy for normal fetal thyroid hormone production ... 1,100 g to be the safe upper limit for ...
Cached Biology News:New biomarker for common lung cancer predicts responses to chemotherapy 2Study associates excess maternal iodine supplementation with congenital hypothyroidism in newborns 2